STE vs TBPH: fair value comparison
STERIS plc and Theravance Biopharma, Inc. · Updated 2026-10-19
TBPH is still awaiting a full valuation verdict under our six-validated-windows standard. Within Healthcare, STE currently ranks higher by quality score.
| STE | TBPH | |
|---|---|---|
| Verdict | Undervalued | Awaiting full valuation |
| Last price | $214.40 | $17.03 |
| 12-month range | $199.40–$268.65 | $13.57–$20.74 |
| Rank by discount to fair value | #25 of 108 Healthcare | — |
| Rank by quality score | #31 of 301 Healthcare | #33 of 301 Healthcare |
| Quality grade | A | A |
| Leverage | Low | Low |
| Margin trend | Stable | Expanding |
| Revenue growth | Modest | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Mixed |
| DCF cross-check | Overvalued | Undervalued |
| 52-week position | The bottom quarter | The lower-middle quarter |
Full single-stock breakdowns: STE fair value analysis · TBPH fair value analysis